investors

Press Releases

DateTitle and SummaryView
December 14, 2016
LOS ANGELES , Dec. 14, 2016 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT:IMUC) announced today that the Board of Directors has appointed Anthony Gringeri , PhD, as Chief Executive Officer and a member of the Board of Directors. Dr.
ImmunoCellular Therapeutics Announces Management Changes
November 21, 2016
Long-Term Survival Data Reported from Phase 1 ICT-107 Trial
ImmunoCellular Therapeutics Reports Updated Immune Monitoring Data from ICT-107 Phase 2 Trial in Newly Diagnosed Glioblastoma at the Society for Neuro-Oncology Annual Meeting 2016
November 16, 2016
LOS ANGELES , Nov. 16, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular " or the "Company") (NYSE MKT: IMUC) announced that at the Special Meeting of Stockholders held on November 14, 2016 , ImmunoCellular's stockholders voted to approve a reverse stock split of the
ImmunoCellular Therapeutics Announces One-for-Forty Reverse Stock Split
November 10, 2016
LOS ANGELES , Nov. 10, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced financial results for the third quarter of 2016 and provided an update on its research and development activities.  Andrew Gengos , ImmunoCellular's Chief Executive
ImmunoCellular Therapeutics Announces Third Quarter 2016 Financial Results and Provides Research and Development Update
November 2, 2016
LOS ANGELES , Nov. 2, 2016 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that it plans to report third quarter 2016 financial results on Thursday, November 10, 2016 . The Company also plans to hold a conference call and webcast on that day
ImmunoCellular Therapeutics to Report Third Quarter 2016 Financial Results on November 10, 2016
August 22, 2016
LOS ANGELES , Aug. 22, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced financial results for the second quarter of 2016.  Andrew Gengos , ImmunoCellular Chief Executive Officer, commented: "We are pleased with the progress we made in the
ImmunoCellular Therapeutics Announces Second Quarter 2016 Financial Results
August 17, 2016
LOS ANGELES , Aug. 17, 2016 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that it plans to report second quarter 2016 financial results on Monday, August 22, 2016 . The Company also plans to hold a conference call and webcast on that day at
ImmunoCellular Therapeutics to Report Second Quarter 2016 Financial Results on August 22, 2016
August 9, 2016
LOS ANGELES , Aug. 9, 2016 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced the pricing of an underwritten public offering of 47,000,000 shares of its common stock and base warrants to purchase up to 35,250,000 shares of its common stock at a
ImmunoCellular Therapeutics Announces Pricing of $7.4 Million Public Offering
July 25, 2016
Over 100 Patients Screened in Phase 3 ICT-107 Trial in Newly Diagnosed Glioblastoma;
CIRM Award Payment of $1.5 Million Received;
ICT-121 Phase 1 Trial in Recurrent Glioblastoma Fully Enrolled
ImmunoCellular Therapeutics Reports Progress in Two Lead Cancer Immunotherapy Programs
June 7, 2016
LOS ANGELES , June 7, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that the first patient has been treated in the phase 3 registrational trial of ICT-107, the Company's lead cancer immunotherapy product candidate, in newly diagnosed
ImmunoCellular Therapeutics Treats First Patient in ICT-107 Phase 3 Registrational Trial in Newly Diagnosed Glioblastoma
Copyright 2018 by Immunocellular Therapeutics, Ltd.
All Rights Reserved